Enable JavaScript to visit this website.

Jump to:

Jump to:

Jump to:

Immunization schedule for infants and children

Are your child’s immunizations up to date?

It is important not to miss vaccine doses.

Vaccines help your child’s immune system produce its own antibodies to help protect him or her from specific diseases.

Following the routine schedule helps protect your child from specific diseases.

Prevnar 13 immunization schedule for infants and toddlers

Prevnar 13 may be given to infants as young as 6 weeks and to children through 5 years of age.

This 3-dose schedule (2+1) may be considered if Prevnar 13
is given as part of a routine immunization program

  1. aMinimum age for dose 1 is 2 months of age.
  2. bRecommended dosing interval is 2 months.
  3. cBooster dose is recommended between 11 and 12 months of age.

For at-risk infants and toddlers, the recommended routine
schedule is a 4-dose schedule (3+1)

  1. aDose 1 may be given as early as 6 weeks of age.
  2. bThe recommended dosing interval is 4-8 weeks.
  3. cThe fourth dose should be administered at approximately 12-15 months, at least 2 months after the third dose.

Prevnar 13 schedule for previously unvaccinated children
≥7 months through 5 years of age

  1. aTwo doses at least 4 weeks apart; third dose after the first birthday and separated from the second dose by at least 2 months.
  2. bTwo doses at least 2 months apart.

Children who have completed the infant series with Prevnar 7 can receive a single dose of Prevnar 13 in the second year of life.

Talk to your healthcare provider about Prevnar 13 for your child.

Children who attend daycare
(under 5 years old) are at increased risk
of IPD.

What is pneumococcal disease?

Any infection caused by the bacteria Streptococcus pneumoniae (S. pneumoniae).
It can lead to these life-threatening diseases:

Prevnar 13 is not indicated to reduce complications of pneumococcal pneumonia, such as death.
What is Prevnar® 13?
Prevnar 13 is a conjugate polysaccharide vaccine administered into the arm or leg muscle. It is used for the prevention of diseases such as bacteraemic pneumonia, sepsis and meningitis caused by 13 types of the bacteria Streptococcus pneumoniae.

How does it work?

Vaccines teach our bodies to recognize and respond to viruses and bacteria, by making products called antibodies that help fight the disease. Our immune system can remember and fight them if they attack in the future.

The Prevnar 13 vaccine works by helping the body make its own antibodies, which protect you against diseases caused by 13 types of the bacteria S. pneumoniae.

Frequently asked questions

Where can I find a clinic?
Vaccines411.ca is an online vaccination clinic locator which also includes reliable immunization resources for Canadians to easily
find the vaccination resources they need. To find a clinic near you, click here.
How many doses of Prevnar 13 are administered to my child?
Infants and children typically should receive 3 or 4 doses of Prevnar 13. According to official recommendations in your province, an alternative schedule may be used by your healthcare provider. It is important to follow the instructions from your healthcare provider so that your child completes the course of injections.
How do I know if my baby has been vaccinated with PREVNAR 13?
Take a look at your baby’s immunization record, as all the vaccines he or she has received should be recorded there.
Also check with your healthcare provider to make sure your baby’s vaccines are up to date.
What do I do if my child has missed a vaccine?
If your child has missed a scheduled vaccine, they could be at risk.
Book an appointment with your doctor’s office or public health office (CLSC in Quebec) as soon as possible.
They can help you figure out which vaccines your child has already had and which ones are needed.
How can I protect my baby against invasive pneumococcal disease?
While invasive pneumococcal diseases can be very serious in babies and young children, PREVNAR 13 can help reduce this risk.
Vaccination with PREVNAR 13 is publicly funded across Canada.

Prevnar 13 safety information

Prevnar 13 should not be used if your child is allergic (hypersensitive) to the active substances, to any other ingredients, or to any other vaccine that contains diphtheria toxoid.

Take special care with Prevnar 13:

  • If your child has any present or past medical problems after any dose of Prevnar 7 or Prevnar 13
  • If your child is sick with a high fever
  • If your child has any bleeding problems

Prevnar 13 will only protect against diseases caused by the types of Streptococcus pneumoniae found in the vaccine. As with any vaccine, Prevnar 13 will not protect 100% of those who receive the vaccine.

Following vaccination with Prevnar 13, children and adolescents may experience redness, pain, tenderness (including impaired movement), swelling or hardness at the vaccination site, fever, irritability, drowsiness, restless sleep, decreased appetite, hives, diarrhea, vomiting and rash.

Talk to your healthcare provider about vaccination with Prevnar 13.

What is invasive pneumococcal disease?

Invasive pneumococcal disease (IPD) occurs when bacteria called Streptococcus pneumoniae invades the brain (meningitis), blood (sepsis), or lungs and blood (bacteraemic pneumonia).

IPD primarily affects children and adults with certain risk factors such as lifestyle or underlying medical conditions, and anyone 65 or older.

In young children, bacteraemia accounts for 50 to 70% of all episodes of IPD, followed by pneumonia (15 to 25%) and meningitis (4%).

In adults, bacteraemic pneumonia accounts for 50 to 80% of all episodes of IPD.

Invasive” disease means germs invade parts of the body that are normally germ-free.


Meningitis is inflammation of the covering of the brain and spinal cord and is generally caused by an infection.

Symptoms include:

  • Stiff neck
  • Fever and headache
  • Pain when looking into bright lights
  • Confusion

In babies, meningitis may cause poor eating and drinking, low alertness and vomiting.


Of children younger than 5 years old who get pneumococcal meningitis:

  • About 1 out of 10 will die from the infection
  • Others may have long-term problems, such as hearing loss or developmental delay

The chance of death increases among elderly patients.


Bacteraemia and sepsis

Bacteraemia and sepsis are infections where bacteria enter the bloodstream.

Symptoms include:

  • Fever
  • Chills
  • Low alertness


About 4 out of 100 children with bacteraemia infection will die from it.

The chance of death is increased among elderly patients.


Bacteraemic pneumonia

Bacteraemic pneumonia is inflammation of one or both of the lungs with pneumococcus bacteria invading and entering the bloodstream. Bacteraemic pneumonia accounts for 12-16% of the cases of IPD in children 2 years of age and younger.

In adults, bacteraemic pneumonia accounts for 50 to 80% of all episodes of IPD.

Symptoms include:
  • Fever and chills
  • Cough
  • Rapid breathing or difficulty breathing
  • Chest pain

Older adults with pneumonia may experience confusion or low alertness, rather than the more common symptoms listed above.


Complications of bacteraemic pneumonia include:
  • Infection of the space between membranes that surround the lungs and chest cavity (empyema)
  • Inflammation of the sac surrounding the heart (pericarditis)
  • Blockage of the airway that allows air into the lungs (endobronchial obstruction)
    • - lung collapse (atelectasis)
    • - collection of pus (abscess) in the lungs

Prevnar 13 is not indicated to reduce complications of pneumococcal disease, including death, neurological complications or hearing loss.


How does it spread?

The Streptococcus pneumoniae bacteria can be passed from person to person through sneezing, coughing or talking. Most people who are exposed to the bacteria do not get sick.

Can invasive pneumococcal disease be treated?

Diseases associated with IPD can be treated with antibiotics.

Although Prevnar 13 can help protect against diseases such as meningitis, sepsis, bacteraemia and bacteraemic pneumonia caused by 13 serotypes of the bacteria Streptococcus pneumoniae, it is not intended to be used in the treatment of active infection.

As with any vaccine, Prevnar 13 may not protect 100% of those who receive the vaccine.